Article Impact Level: HIGH Data Quality: STRONG Summary of Langmuir, 41(18), 11253–11271. https://doi.org/10.1021/acs.langmuir.4c03005 Dr. Avisankar Chini et al.
Points
- Chronic inflammation significantly impairs the ability of immune cells, specifically macrophages, to properly process cholesterol, a factor that contributes substantially to the development of various cardiovascular and metabolic diseases.
- The enzyme indoleamine-2,3-dioxygenase 1 (IDO1) becomes highly activated during inflammation, directly contributing to the disruption of normal cellular functions related to lipid regulation.
- IDO1 activation leads to the production of a substance called kynurenine that interferes with cholesterol uptake by downregulating the key transport receptor SR-BI on macrophages.
- Experimental inhibition of the IDO1 enzyme successfully restored SR-BI expression and the macrophages’ ability to absorb cholesterol, suggesting a promising new therapeutic pathway for intervention.
- Targeting IDO1 could lead to novel treatments for heart disease and other chronic illnesses by controlling inflammation and maintaining a healthy cholesterol balance within the body.
Summary
New research reveals a crucial connection between inflammation, tryptophan metabolism, and cholesterol dysregulation in macrophages. The study demonstrates that the expression of the high-density lipoprotein receptor SR-BI, which is crucial for reverse cholesterol transport, is significantly reduced in macrophages under inflammatory conditions induced by LPS or IFN-γ. This reduction in SR-BI expression impairs the cells’ ability to uptake cholesterol. It is regulated by the activation of the NF-κB pathway, contributing to a pro-atherogenic cellular environment.
The central mechanism identified in this process is the enzyme indoleamine-2,3-dioxygenase 1 (IDO1). During inflammation, IDO1 expression is elevated, leading to an increase in the tryptophan catabolite kynurenine (KYN). This IDO1-KYN axis was found to be directly responsible for suppressing SR-BI expression. Critically, experimental knockdown or pharmacological inhibition of IDO1 successfully reversed these effects, leading to a downregulation of the inflammatory response, a decrease in KYN levels, and a subsequent restoration of both SR-BI expression and cholesterol uptake functionality in macrophages.
These findings position IDO1 as a key therapeutic target for managing diseases driven by chronic inflammation and lipid dysregulation, such as atherosclerosis. The study further suggests that nitric oxide synthase (NOS), another pro-inflammatory enzyme, may exacerbate the effects of IDO1, presenting an additional target for intervention. Future research will focus on developing safe and effective IDO1 inhibitors to translate these findings into novel treatments for cardiovascular disease, diabetes, and other inflammation-related conditions by restoring cholesterol homeostasis in immune cells.
Link to the article: https://pubs.acs.org/doi/10.1021/acs.langmuir.4c03005
References Chini, A., Guha, P., Rishi, A., Bhat, N., Covarrubias, A., Martinez, V., Devejian, L., Nguyen, B. N., & Mandal, S. S. (2025). Hdlr-sr-bi expression and cholesterol uptake are regulated via indoleamine-2,3-dioxygenase 1 in macrophages under inflammation. Langmuir, 41(18), 11253–11271. https://doi.org/10.1021/acs.langmuir.4c03005
